Circulating Cell-Free DNA-Based Detection of Tumor Suppressor Gene Copy Number Loss and Its Clinical Implication in Metastatic Prostate Cancer

Xiaoxi Dong, Tiantian Zheng, Minhua Zhang, Chao Dai, Lili Wang, Lei Wang, Ruipeng Zhang, Yuan Long, Danyi Wen, Feng Xie, Yue Zhang, Yong Huang, Jianguo Dong, Huan Liu, Pan Du, Bonnie L. King, Winston Tan, Shidong Jia, Chris X. Lu, Manish KohliHaitao Wang, Jianjun Yu

Research output: Contribution to journalArticlepeer-review

Abstract

Current liquid biopsy assays lack sufficient sensitivity to detect copy number loss, which limits the interrogation of critical tumor suppressor gene deletions during cancer progression and treatment. Here we describe a liquid biopsy assay with improved sensitivity for detection of copy number loss in blood samples with low levels of circulating tumor DNA, and demonstrate its utility by profiling PTEN, RB1, and TP53 genetic loss in metastatic prostate cancer patients.

Original languageEnglish (US)
Article number720727
JournalFrontiers in Oncology
Volume11
DOIs
StatePublished - Aug 24 2021

Keywords

  • circulating tumor DNA
  • copy number loss
  • liquid biopsy
  • NGS
  • prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Circulating Cell-Free DNA-Based Detection of Tumor Suppressor Gene Copy Number Loss and Its Clinical Implication in Metastatic Prostate Cancer'. Together they form a unique fingerprint.

Cite this